https://finance.yahoo.com/news/praxis-precision-medicines-announces-topline-123000869.html
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3...
Create an account or login to join the discussion